Journal
FUTURE MICROBIOLOGY
Volume 9, Issue 8, Pages 969-985Publisher
FUTURE MEDICINE LTD
DOI: 10.2217/FMB.14.70
Keywords
attenuation; drug development; evolution; Mycobacterium tuberculosis; secretion systems; virulence factors
Categories
Funding
- Fondation pour la Recherche Medicale FRM [DEQ20130326471]
- European Community's (EC) [MM4TB 260872]
- Agence Nationale pour la Recherche (France) [09 BLAN 0400 01]
- French Region Ile-de-France (Domaine d'Interet Majeur Maladies Infectieuses et Emergentes) PhD program
Ask authors/readers for more resources
Mycobacterium tuberculosis, the etiological agent of human TB, is the most important mycobacterial pathogen in terms of global patient numbers and gravity of disease. The molecular mechanisms by which M. tuberculosis causes disease are complex and the result of host-pathogen coevolution that might have started already in the time of its Mycobacterium canettii-like progenitors. Despite research progress, M. tuberculosis still holds many secrets of its successful strategy for circumventing host defences, persisting in the host and developing resistance, which makes anti-TB treatment regimens extremely long and often inefficient. Here, we discuss what we have learned from recent studies on the evolution of the pathogen and its putative new drug targets that are essential for mycobacterial growth under in vitro or in vivo conditions.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available